Pliant Therapeutics

View All

pharma-news
Gene-edited T cells for diabetes treatment; Pliant raised $144 million; Accent, AstraZeneca aim RNA modifiers in cancer deal; NodThera Raises $55M;

Gene-edited T cells for diabetes treatment The Scientists at the Seattle Children's Research Institute and the Benaroya Research Institute have got a promising finding that will turn off the destructive autoimmune response in Type 1 diabetes. This comprises editing the genes of patients' T cells. The team pre...

Find More